跳至主要内容
临床试验/NCT04342923
NCT04342923Unknown不适用

Early POstoperative BIomarkers in PancreatoDuodenectomy as Predictors of Complications: a Spanish Nationwide Multicentric Validation Study

Hospital Clínico Universitario de Valladolid1 个研究点 分布在 1 个国家目标入组 525 人开始时间: 2021年3月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
525
试验地点
1
主要终点
Pancreatic fistula rate

研究概览

简要总结

AIMS: To recruit a large nationwide Spanish series in order to register PF rate and other common morbidity after PD, and to perform external validation of the aforementioned score, as well as to analyze other postoperative blood parameters and biomarkers associated with complications.

METHODS: Observational prospective and multicentric cohort study to perform external validation of the above-mentioned score. All Spanish centers/units performing PD are invited to include participants. Patients will be consecutively recruited during an 8-10 months period, regardless of their annual volume of pancreatic surgery.

Study variables will be hemogram parameters on POD1 and POD2 (specifically lymphocytes), other parameters and biomarkers (RCP, lactate, procalcitonin, amylase, lipase, albumin) and the common variables concerning PD studies.

LIMITATIONS: Heterogeneity in perioperative management and in blood analysis measuring since this is a multicenter study. Possibility of underestimating the PF rate in patients without surgical drainage. Finally, the cases of mini-invasive approach or pancreatogastrostomy will receive a specific subgroup analysis since the score was designed on a series of open PD and pancreatojejunostomy.

详细描述

BACKGROUND: Complications after pancreatoduodenectomy (PD) are common and pancreatic fistula (PF) is among the most relevant ones. There are few studies analyzing blood parameters determined in the early postoperative period which behave as morbidity predictors. One of them defined a new and simple prognostic score based on lymphocytes count on the first postoperative day (POD1) and reactive C protein (RCP) on POD2. The internal validation statistics of the score designed in the mentioned work were satisfactory. However, that score was described in a short unicentric series

EXPECTED SAMPLE SIZE: Expected sample size is approximately 500 patients, which will show error <7.2% (with 95% confidence) for estimation score´s sensitivity and specificity. We have assumed that the PF rate is around 30%.

QUALITY CONTROL: The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines for the correct communication and publication of observational studies will be followed. Likewise, in order to validate the aforementioned score, Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) will be added. The only expected failure of the 20 items that compose the TRIPOD is 6b ("notify the actions for masking the analysis"), since it is not applicable in our case.

The inclusion of patients operated on with a mini-invasive approach (laparoscopic or robotic) or the use of other anastomoses (pancreatogastrostomy) or reconstruction (Roux-en-Y) differs from the technique used in the series with which the score was originally defined (allof them, open PD with pancreato-jejunostomy and, mostly part, tutored ducto-mucosal suture and Child's single loop reconstruction). If discrepancies are detected, the corresponding subgroup analysis will be performed. Cases of conversion from a mini-invasive to open approach will be counted as such (intention-to-treat analysis).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • benign or malignant condition requiring surgical treatment by PD.
  • Signing the informed consent form

排除标准

  • Intra-operative findings of unresectability (pancreatic resection not be completed or palliative procedure performed)
  • Other types of pancreatic resection (enucleations, distal and total pancreatectomies), as well as multivisceral resective procedures.
  • Intraoperative radiotherapy
  • ASA IV patients

结局指标

主要结局

Pancreatic fistula rate

时间窗: 90 days since PD

Pancreatic fistula including biochemical, grade B and grade C according to ISGPS updated criteria 2016

次要结局

  • Overall complications(90 days since PD)
  • Mortality(90 days since PD)
  • Clinically relevant pancreatic fistula(90 days since PD)
  • Severe morbidity(90 days since PD)
  • Comprehensive Complication Index(90 days since PD)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mario Rodriguez-Lopez

General and Digestive Surgeon, MD, PhD

Hospital Clínico Universitario de Valladolid

研究点 (1)

Loading locations...

相似试验